Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Newly Diagnosed multiple Myeloma
100%
Confidence Interval
70%
Hazard Ratio
40%
Overall Survival
20%
Graft-versus-host Disease (GvHD)
20%
Multiple Myeloma Patients
20%
Multivariable
10%
Multiple Myeloma
10%
Selected Populations
10%
Survival Benefit
10%
Median Overall Survival
10%
Complete Remission
10%
Survivors
10%
Partial Response
10%
Progression-free Survival
10%
Disease Course
10%
Median Progression-free Survival
10%
Am(III)
10%
Median Time
10%
Unrelated Donor
10%
Non-relapse Mortality
10%
Nonmyeloablative
10%
Reduced-intensity Conditioning
10%
Cumulative Incidence
10%
First Remission
10%
Consolidation Therapy
10%
Novel Agents
10%
Consolidation Treatment
10%
Hematopoietic Cell Transplantation
10%
Long Progression-free Survival
10%
Annualized Relapse Rate
10%
Chemosensitive
10%
High-risk Cytogenetics
10%
Donor Graft
10%
High-risk Myeloma
10%
Medicine and Dentistry
Multiple Myeloma
100%
Hematopoietic Cell
100%
Cell Transplantation
100%
Hazard Ratio
36%
Overall Survival
27%
Progression Free Survival
27%
Cumulative Incidence
18%
Diseases
9%
Disease Course
9%
Reduced Intensity Conditioning
9%
Acute Graft Versus Host Disease
9%
Chronic Graft Versus Host Disease
9%
Immunology and Microbiology
Hematopoietic Cell
100%
Multiple Myeloma
100%
Cell Transplantation
100%
Overall Survival
27%
Progression Free Survival
27%
Conditioning
9%
Acute Graft Versus Host Disease
9%
Chronic Graft Versus Host Disease
9%
Neuroscience
Hematopoietic Cell
100%
Cytogenetics
9%